Popular search terms:
Search Results
93 results found-
CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.
https://www.cslseqirus.us/products -
CSL Seqirus confirms it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the Vaccines and Related Biological Products Advisory Committee (VRBPAC).
https://www.cslseqirus.us/news/csl-seqirus-fully-prepared-to-implement-fdas-tiv-strain-selection-for-202425-us-season -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news -
Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.
https://www.cslseqirus.us/expertise/influenza -
CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.cslseqirus.us/expertise -
Data evaluating the impact of cell-based quadrivalent influenza vaccines suggests an additional 31%–39% of influenza cases may have been prevented among persons 0–64 years of age during the 2017-2020 U.S. flu seasons.
https://www.cslseqirus.us/news/idweek-2023-demonstrates-public-health-benefit-cost-savings-cell-based-and-adjuvanted-flu-vaccines -
The U.S. Food and Drug Administration (FDA), in collaboration with the World Health Organization (WHO), has directed influenza vaccine manufacturers to remove the B/Yamagata influenza virus strain from all influenza vaccines distributed in the United States, as soon as possible, preferably by the 2024/25 influenza season.
https://www.cslseqirus.us/news/csl-seqirus-to-remove-byamagata-influenza-virus-strain-from-portfolio-of-influenza-vaccines -
The company is positioned to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.
https://www.cslseqirus.us/news/csl-seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-2023-24-us-season -
Results from a retrospective cohort study from 2015 to 2020 demonstrated a notable rise with increasing age in pneumonia-related medical encounters following an influenza encounter.
https://www.cslseqirus.us/news/csl-seqirus-presents-rwe-at-eswi-demonstrating-impact-of-influenza-vaccination-campaigns -
CSL Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.cslseqirus.us/partnering